HB3759 amends the Illinois Food, Drug and Cosmetic Act to make it a violation of state law to contract to delay the entry of a drug into the marketplace. In practical terms, the bill targets agreements that postpone a drug’s availability, which are often associated with “pay-for-delay” or similar anti-competitive arrangements in the pharmaceutical industry.
The bill adds a new prohibited act to the Act’s list of unlawful conduct and makes a corresponding change to the statute’s general prohibition section. It would therefore expand the enforcement reach of Illinois drug law by giving the state a clearer basis to treat delay agreements as unlawful conduct under the Food, Drug and Cosmetic Act.
Impact
If enacted, HB3759 would amend 410 ILCS 620/3 and create a new Section 3.21a in the Illinois Food, Drug and Cosmetic Act. The main legal effect would be to prohibit contracts whose purpose or effect is to delay a drug’s entry into the marketplace, potentially affecting pharmaceutical manufacturers, brand-name and generic drug companies, and any entities involved in drug licensing or settlement agreements. The bill would strengthen state-level oversight of drug market competition and could support enforcement actions against anti-competitive delay arrangements.
Sentiment
There is no recorded committee transcript or vote history in the provided materials, so no formal debate or recorded opposition is available. Based on the bill’s caption and text, the measure appears aimed at consumer protection and lowering barriers to drug access, which typically draws support from those concerned about prescription drug prices and competition. Because no votes or hearing comments are included, the overall sentiment cannot be measured beyond the bill’s apparent pro-competition purpose.
Contention
The likely point of contention is whether the bill’s prohibition is broad enough to capture legitimate business settlements or licensing arrangements without discouraging lawful patent or market-entry negotiations. Pharmaceutical companies and other industry stakeholders may argue that such restrictions could interfere with intellectual property rights or settlement practices, while consumer advocates and competition-focused supporters would likely favor the bill as a way to prevent delayed access to lower-cost drugs. No specific objections or supporters are identified in the provided record.